 |
 |
7:00 AM - 8:30 AM
Oral Session, 353-355: Clinical Care - Transplantation Regimen Toxicities and Engraftment: Novel Reduced Intensity Protocols
194 Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients Aged ≥60 Years: a Retrospective Study of 629 Patients From the Societe Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC). Patrice Chevallier, et al.
195 Comparison of Outcomes After Allogeneic HSCT for Adult Patients with AML in Remission Using in the Conditioning Regimen Either I.V. Busulfex (BU) Plus Cyclophosphamide (Cy) or TBI Plus Cy: An- ALWP-EBMT Survey. Arnon Nagler, et al.
Oral Session, 220-222: Hemoglobinopathies, excluding Thalassemia: Vascular and Organ Dysfunction
259 Low Levels of Apolipoprotein A1 Are Associated with Silent Cerebral Infarcts in Children with Sickle Cell Disease. John J. Strouse, et al.
262 Elevated Systolic Blood Pressure and Low Fetal Hemoglobin Are Risk Factors for Silent Cerebral Infarcts in Children with Sickle Cell Anemia. Sharada A. Sarnaik, et al.
10:30 AM - 12:00PM
Oral Session, 391-392: Experimental Transplantation - Basic Biology, Immune Function, and Engraftment: Insights Into Mechanisms of Stem Cell Mobilization, Homing and Expansion
369 Human Umbilical Cord Blood Stem Cell Function Is Augmented by Exposure to Prostaglandin E2. Wolfram Goessling, et al.
370 In Vivo Treatment with Chromatin Modifying Agents Dramatically Increases Hematopoietic Stem Cell Numbers. Benjamin Petro, et al.
2:45 PM - 4:15 PM
Oral Session, 388-390: Cell Processing: Ex Vivo Expansion
499 Significant Ex-Vivo Expansion and Functional Activation of Cord Blood (CB) Natural Killer (NK) Cells with A Concomittant Significant Decrease in CB T Cells Following Stimulation with Genetically Engineered K562 Cells (K562-mb15-41BBL). Jessica Hochberg, et al.
500 Ex Vivo Expansion of Human Hematopoietic Stem Cells by a Small-Molecule Agonist of c-MPL. Taito Nishino, et al.
503 Long-Term in Vitro Cytokine-Free and Serum-Free Culture of Human Cord Blood Mononuclear Cells in a Three-Dimensional Scaffold. Teresa Mortera-Blanco, et al.
504 Cytotoxic T Lymphocytes (CTL) Specific for CMV, Adenovirus, and EBV Can Be Generated From Naive T Cells for Adoptive Immunotherapy. Patrick Hanley, et al.
Oral Session, 243-245: Clinical Care - Acute and Chronic GVHD, Infectious Complications and Immune Reconstitution of Transplantation: Immunology of Acute and Chronic Graft-versus-Host Disease
513 Adoptive Transfer of Umbilical Cord Blood (UCB)-Derived Regulatory T Cells (Tregs) to Recipients of Nonmyeloablative Unrelated Double UCB Transplantation. Claudio Brunstein, et al.
516 Low Absolute CD4 Central Memory Count On Day 30 Is Associated with An Increased Incidence of Chronic Graft-Versus-Host Disease. Zachariah A. McIver, et al.
Oral Session, 208-210: Clinical Care, Recurrence, Secondary Neoplasia and Late Complications After Transplantation II
517 Population-Based Analysis of Late Cardiovascular Morbidity and Hospitalizations After Hematopoietic Cell Transplantatio. Eric J Chow, et al.
518 Long-Term Survival and Late Events After Allogeneic Stem-Cell Transplantation with Reduced-Intensity Conditioning (RIC) for AML and Mds; Comparable Results with Myeloablative Conditioning. Avichai Shimoni, et al.
519 Male Gender, Quality of Grafted Cells, Advanced Age, Rituximab and Radiotherapy Are the Main Factors That Variously Influence the Occurrence of Secondary Malignancies Following High-Dose Therapy and Autograft: A GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) Survey in 1,347 Lymphoma Patients. Corrado Tarella, et al.
520 Long-Term Survival and Late Deaths in 2-Year Survivors of Myeloablative Allogeneic Hematopoietic-Cell Transplantation for Hematologic Disorders. John R. Wingard, et al.
521 Neurocognitive Function and Its Impact On Return to Work in Patients Treated with Hematopoietic Cell Transplantation (HCT). F. Lennie Wong, et al.
522 Development of Psycho-Intellectual Performances of Transplanted Sickle Cell Disease Patients: a Prospective Study From Pre-Transplant Period to 5 Years After HSCT. Jacqueline Bockenmeyer, et al.
Oral Session, 271-273: Clinical Results - Alternative Donor Transplantation I
523 Outcome of Reduced Intensity Allografts in Patients Aged Over 45 Years with Acute Myeloid Leukaemia: Initial Results of the MRC AML15 Trial. Nigel H. Russell, et al.
524 Comparison of Allogeneic Hematopoietic Cell Transplantation and Chemotherapy as Post-Remission Strategy in Elderly Patients with Non-M3 AML in CR1: Retrospective Analysis with 1036 Patients. Saiko Kurosawa, et al.
525 Monosomal Karyotype Provides Better Prognostic Prediction After Allogeneic Stem Cell Transplantation in AML Patients. Betul Oran, et al.
526 Comparable Disease-Free and Overall Survival After “Well-Matched” Unrelated Donor and Matched Sibling Donor Transplantation in Acute Myeloid Leukemia with Adverse Risk Karyotype in First Complete Remission: A Report From the Acute Leukemia Working Committee of the Centre for International Blood and Marrow Transplant Research. Vikas Gupta, et al.
4:30 PM - 6:00 PM
Oral Session, 293-296: Clinical Results - Allogeneic Matched Related Donor Transplantation: Novel Approaches and Applications
656 Targeted Lymphocyte Depletion: A Personalized Approach to Achieve Rapid Complete Donor Chimerism and Enhance Graft-Versus-Tumor Effects Following Reduced Intensity Allogeneic Stem Cell Transplantation for High-Risk Hematologic Malignancies. Rachel B. Salit, et al.
657 Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Compared to Chemotherapy Only in Acute Myeloid Leukemia (AML) Patients 60 Years and Older: A Center for International Blood and Marrow Transplantation Research (CIBMTR)/ Cancer and Leukemia Group B (CALGB) Study. Sherif Farag, et al.
659 Risk Stratification without a Liver Biopsy of Patients with β Thalassemia Major Undergoing a Matched Related Allogeneic Bone Marrow Transplant. Vikram Mathews, et al.
660 First Use of Allogeneic Stem Cells in the Treatment of Recessive Dystrophic Epidermolysis Bullosa: Demonstration of Biochemical and Clinical Improvement. John E. Wagner, et al.
Oral Session, 275-277: Clinical Results - Alternative Donor Transplantation II
661 Re-Exposure of Cord Blood (CB) to Non-Inherited Maternal HLA Antigens (NIMA) Improves Transplant Outcome in Patients (pts) with Hematologic Malignancies and May Reduce Relapse. Jon J van Rood, et al.
662 Reduced Relapse and Similar Progression-Free Survival After Double Umbilical Cord Blood Transplantation (DUCBT): Comparison of Outcomes Between Sibling, Unrelated Adult and Unrelated DUCB Hematopoietic Stem Cell (HSC) Donors. Claudio G. Brunstein, et al.
663 Comparison of Outcomes After Unrelated Cord Blood Transplantation and Matched Unrelated Donor RIC Transplantation for Lymphoid Malignancies - A Eurocord-Netcord Group/ Lymphoma Working Party and Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Study. Celso Arrais Rodrigues, et al.
664 Comparison of Outcomes of Mismatched Related Stem Cell and Unrelated Cord Blood Transplants in Children with Severe T-Cell Deficiencies. Juliana Folloni Fernandes, et al.
665 Selection of Donors with Favorable KIR B Genotypes for Unrelated Hematopoietic Cell Transplantation Results in Superior Relapse Protection and Better Relapse-Free Survival for Patients with AML. Sarah Cooley, et al.
6:00 PM - 8:00 PM
Poster Session, Hall E: Bone Marrow Failure Poster II
3201 Impact of Nucleated Cell Dose On Engraftment and Survival After Unrelated Cord Blood Transplantation for Severe Aplastic Anemia: A Retrospective Study On Behalf of Eurocord and the EBMT SAA WP. Regis Peffault de Latour, et al.
Poster Session, Hall E: Cell Processing Poster II
3212 Adverse Events Following Infusion of T Cells for Adoptive Immunotherapy: A 10 Year Experience. Conrad Russell Y. Cruz, et al.
3217 Creation of a Segment-Based Aldehyde Dehydrogenase Assay as a Biomarker for Cord Blood Potency. Kevin Shoulars, et al.
3222 In Vitro Large-Scale Expansion of Unfractionated Mononucleated Cells of Human Umbilical Cord Blood: Investigation for Clinical-Grade Generation of Cord Blood Hematopoietic Cells. Ping Mao, et al.
3232 Reevaluation of Factors Leading to the Successful Isolation of Mesenchymal Stem Cells From Human Umbilical Cord Blood and Their Differentiation to Mesenchymal Lineages. Xiaohong Zhang, et al.
Poster Session, Hall E: Clinical Care - Transplantation Regimen Toxicities and Engraftment Poster III
3331 Effectiveness of Reduced Toxicity Conditioning Regimen with Intravenous Busulfan Plus Pentostatin (BUPENT) in Patients Older Than 50 Years with Advanced Hematologic Malignancies. Tulio E. Rodriguez, et al.
3335 Busulfan/Fludarabine/Thymoglobulin as a Reduced Intensity Conditioning Regimen for Lymphoid Malignancies. Jeevan Sekhar, et al.
3336 Comparison of Pre-Cryopreserved and Post Thaw and Wash Total Nucleated Cell Count On Major Outcomes Following Unrelated Cord Blood Transplant in Children. Meghann S. Pine, et al.
3338 Early Engraftment Kinetics of Leukocyte Subsets by Means of HLA-Specific Mabs After Double Umbilical Cord Blood Transplantation Show a Very Rapid Induction of Single Complete Donor Chimerism. Judith AE Somers, et al.
3341 Fludarabine, Low Dose Busulfan and Antithymocyte Globulin for Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT). F. Malard, et al.
Poster Session, Hall E: Clinical Results - Alternative Donor Transplantation Poster III
3376 The Intra-Bone Route of Administration of Cord blood cells extends the Possibility of Transplantation to the Majority of Patients with Malignant Hematopoietic Diseases. Francesco Frassoni, et al.
3378 Allogeneic Hematopoietic Cell Transplantation From Combined Haploidentical Family Members and Unrelated Cord Blood (CB) Can Benefit High Risk Patients Lacking HLA-Identical Donors. Elizabeth Shima Rich, et al.
3381 Comparative Analysis of Outcomes of Allogeneic Peripheral Blood Stem Cell Transplantation From Related and Unrelated Donors. Byung Woog Kang, et al.
3382 Comparative Single Institute Analysis of Cord Blood Transplantation From Unrelated Donors with Unrelated Bone Marrow or Related Peripheral Blood Stem-Cell Transplants in Adult Patients with Acute Myeloid Leukemia / Myelodysplastic Syndrome. Kazuhiro Masuoka, et al.
3384 FluBup-ATG-TBI for High-Risk or Advanced Adult ALL in Remission: A Retrospective Review of a Mature Cohort. Andrew Daly, et al.
3385 Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia: Similar Efficacy of Non-Myeloablative and Myeloablative Conditioning; Long-Term Evaluation From the University of Minnesota. Brian McClune, et al.
3386 Impact of Early Lymphocyte Recovery On Transplant Outcome After Cord Blood Transplantation. Sara K Tedeschi, et al.
3388 Long Term Results of Allogeneic Hematopoietic Cell Transplantation in Elderly Patients. Michael Stadler, et al.
3393 Outcome of HLA-Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation Depends On the Intensity of the Conditioning Regimen. Francis Ayuk, et al.
3394 Rapid Engraftment of Neutrophils and Platelets with Mesenchymal Stem Cell Based Cord Blood (CB) Expansion (EXP). Marcos de Lima, et al.
Poster Session, Hall E: Experimental Transplantation - Basic Biology, Immune Function, and Engraftment Poster II
3525 Adoptive Therapy with T-Cell Precursors for Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation. Emanuela Burchielli., et al.
3533 Irradiated Third Party Peripheral Blood Mononuclear Cells Enhance Umbilical Cord Blood Engraftment. Tulin Budak-Alpdogan, et al.
3541 Quantitative Analysis of Chimerism Using Insertion/Deletion Polymorphisms Is An Useful Predictor of Relapse After Allogeneic Stem Cell Transplantation for Acute Leukemia. Nathalie Jacque, et al.